BACKGROUND: We aimed to investigate the correlations between ACE2 polymorphisms and type 2 diabetes mellitus (T2DM) combined with cerebral stroke (CS). METHODS: A total of 346 patients treated or hospitalized in our hospital were enrolled, including 181 cases without cerebrovascular complications (T2DM group) and 165 cases combined with CS (T2DM + CS group); 284 healthy individuals were selected as the control group. PCR-RFLP and ELISA were used to analyze ACE2 G8790A polymorphisms and serum ACE2 levels, respectively. RESULTS: Significant differences were observed in the genotype/allele frequency of ACE2 G8790A between the T2DM + CS and control groups, and the T2DM and T2DM + CS groups, and in the genotype frequency of ACE2 G8790A between the T2DM and the control groups. The A allele may increase the risk of T2DM combined with CS. The AA genotype may also increase the risk of T2DM combined with CS (OR = 3.733, 95%CI = 2.069-6.738; OR = 3.597, 95%CI = 1.884-6.867). Serum ACE2 levels showed statistically significant differences among the groups. Systolic pressure and diastolic pressure were protective factors of T2DM combined with CS. CONCLUSION: The ACE2 G8790A polymorphism in T2DM patients was correlated with CS, and the A allele might be a risk factor of T2DM combined with CS.
BACKGROUND: We aimed to investigate the correlations between ACE2 polymorphisms and type 2 diabetes mellitus (T2DM) combined with cerebral stroke (CS). METHODS: A total of 346 patients treated or hospitalized in our hospital were enrolled, including 181 cases without cerebrovascular complications (T2DM group) and 165 cases combined with CS (T2DM + CS group); 284 healthy individuals were selected as the control group. PCR-RFLP and ELISA were used to analyze ACE2G8790A polymorphisms and serum ACE2 levels, respectively. RESULTS: Significant differences were observed in the genotype/allele frequency of ACE2G8790A between the T2DM + CS and control groups, and the T2DM and T2DM + CS groups, and in the genotype frequency of ACE2G8790A between the T2DM and the control groups. The A allele may increase the risk of T2DM combined with CS. The AA genotype may also increase the risk of T2DM combined with CS (OR = 3.733, 95%CI = 2.069-6.738; OR = 3.597, 95%CI = 1.884-6.867). Serum ACE2 levels showed statistically significant differences among the groups. Systolic pressure and diastolic pressure were protective factors of T2DM combined with CS. CONCLUSION: The ACE2G8790A polymorphism in T2DMpatients was correlated with CS, and the A allele might be a risk factor of T2DM combined with CS.
Authors: Angela D Liese; Ralph B D'Agostino; Richard F Hamman; Patrick D Kilgo; Jean M Lawrence; Lenna L Liu; Beth Loots; Barbara Linder; Santica Marcovina; Beatriz Rodriguez; Debra Standiford; Desmond E Williams Journal: Pediatrics Date: 2006-10 Impact factor: 7.124
Authors: Arnold C T Ng; Victoria Delgado; Matteo Bertini; Rutger W van der Meer; Luuk J Rijzewijk; See Hooi Ewe; Hans-Marc Siebelink; Johannes W A Smit; Michaela Diamant; Johannes A Romijn; Albert de Roos; Dominic Y Leung; Hildo J Lamb; Jeroen J Bax Journal: Circulation Date: 2010-11-29 Impact factor: 29.690
Authors: Dana Dabelea; Ronny A Bell; Ralph B D'Agostino; Giuseppina Imperatore; Judith M Johansen; Barbara Linder; Lenna L Liu; Beth Loots; Santica Marcovina; Elizabeth J Mayer-Davis; David J Pettitt; Beth Waitzfelder Journal: JAMA Date: 2007-06-27 Impact factor: 56.272
Authors: Daniela Milani; Lorenzo Caruso; Enrico Zauli; Adi Mohammed Al Owaifeer; Paola Secchiero; Giorgio Zauli; Donato Gemmati; Veronica Tisato Journal: Front Pharmacol Date: 2022-05-27 Impact factor: 5.988
Authors: Juan Gómez; Guillermo M Albaiceta; Marta García-Clemente; Carlos López-Larrea; Laura Amado-Rodríguez; Inés Lopez-Alonso; Tamara Hermida; Ana I Enriquez; Pablo Herrero; Santiago Melón; Marta E Alvarez-Argüelles; José A Boga; Susana Rojo-Alba; Elías Cuesta-Llavona; Victoria Alvarez; Rebeca Lorca; Eliecer Coto Journal: Gene Date: 2020-08-31 Impact factor: 3.688